1. National Institute for Health and Care Excellence. Empagliflozin. Available at: https://bnf.nice.org.uk/drug/empagliflozin.html (accessed 20 November 2019).
2. Ray G M, Rodriguez C, Schulman S M, Sarangarm P, Bardack M, Bouchonville M F. Empagliflozin-induced diabetic ketoacidosis unmasking a type 1 diabetes diagnosis. Clin Pract Cases Emerg Med 2019; 3: 140-143.
3. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis. 18 April 2016. Available at: https://www.gov.uk/drug-safety-update/sglt2-inhibitors-updated-advice-on-the-risk-of-diabetic-ketoacidosis (accessed 22 January 2020).
4. Anthony S, Dixit D. Understanding SGLT2 inhibitors' diabetic ketoacidosis risk. Pharmacy Times 16 August 2016. Available at: https://www.pharmacytimes.com/contributor/deepali-dixit-pharmd-bcps/2016/08/understanding-sglt2-inhibitors-diabetic-ketoacidosis-risk (accessed 21 January 2020).